Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa.
Arriola-Villalobos
P
P
Díaz-Valle
D
D
Alejandre-Alba
N
N
López-Abad
C
C
Méndez-Fernández
R
R
Benítez-del-Castillo
J M
JM
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D002177:Candidiasis / Q000139:chemically induced*; D002825:Chorioretinitis / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept